Skip to content

MannKind

US · MNKD #3124 by market cap Listed 2016
3.45 -0.26 -7.01%
Live - 5344 symbols - heartbeat 250s ago · 2026-10-08 04:41
Pre-market 3.48 +0.87%
After-hours 3.46 +0.29%
Overnight 3.49 +1.16%
Market cap
1.11B
P/B
-16.51
EPS
0.02
Reader sentiment Are you bullish or bearish on MNKD?

Anonymous reader poll. Unscientific, not investment advice.

Valuation each multiple against its own 5-year range

P/B ratio -17.75 Cheap vs history 26th percentile
5-year average -11.32
P/E ratio -26.50 Cheap vs history 18th percentile
5-year average 16.52 · forward -33.54
P/S ratio 3.03 Cheap vs history 6th percentile
5-year average 8.14 · forward 2.33 · #68 of 388 in Biotechnology

Vs. peers Biotechnology

Company Market cap P/E (TTM) P/B Div yield
MannKind (MNKD) 1.11B -24.64 -16.51 0.00%
Vertex Pharmaceuticals (VRTX) 128.16B 29.45 6.33 0.00%
Moderna (MRNA) 78.44B -24.62 11.60 0.00%
Regeneron Pharmaceuticals (REGN) 76.40B 18.36 2.41 0.49%
argenx SE (ARGX) 58.39B 35.37 6.94 0.00%
Revolution Medicines (RVMD) 43.05B -22.65 16.52 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value3.73 Economic moatNone UncertaintyHigh

Trading 8.1% below Morningstar's fair value estimate.

Fair value

MannKind Corp earns a 3-star quantitative star rating, illustrating our stance that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a price consistent with our quantitative fair value estimate, which has a high uncertainty rating.

The company's valuation metrics weaken our estimated fair value. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. Reflecting the firm's valuation is its enterprise value to EBITDA ratio of 29.8, which lies in the top 20% globally. This suggests that the value of its enterprise value, or the value of its shares and debt, is a high multiple of the generated EBITDA. This contributes to our balanced fair value estimate.

The firm's lack of profitability is an additional cause for concern. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. The firm's earnings yield of 1.4%, for example, sits in the bottom 40% compared with global peers. The earnings generated by the company relative to its share price is concerning, which further promotes our neutral price/fair value ratio.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. While we believe the stock is fairly-valued, this outperformance had a negative impact on our valuation estimate.

Economic moat

With its quantitative economic moat rating of none, this business is unlikely to consistently outearn its cost of capital without structural protection from competition. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-10-08 04:41:42 · For reference only, not investment advice and not tailored to your situation.